key: cord-0769433-3cz34tk4
authors: Li, Rong; Wu, Ka; Li, Yu; Liang, Xiao; Lai, Keng Po; Chen, Jian
title: Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses
date: 2020-07-14
journal: Brief Bioinform
DOI: 10.1093/bib/bbaa141
sha: 642242bb4f3fea2aed802d1e79ecb6cec7e3525b
doc_id: 769433
cord_uid: 3cz34tk4

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a fatal and fast-spreading viral infection. To date, the number of COVID-19 patients worldwide has crossed over six million with over three hundred and seventy thousand deaths (according to the data from World Health Organization; updated on 2 June 2020). Although COVID-19 can be rapidly diagnosed, efficient clinical treatment of COVID-19 remains unavailable, resulting in high fatality. Some clinical trials have identified vitamin C (VC) as a potent compound pneumonia management. In addition, glycyrrhizic acid (GA) is clinically as an anti-inflammatory medicine against pneumonia-induced inflammatory stress. We hypothesized that the combination of VC and GA is a potential option for treating COVID-19. METHODS: The aim of this study was to determine pharmacological targets and molecular mechanisms of VC + GA treatment for COVID-19, using bioinformational network pharmacology. RESULTS: We uncovered optimal targets, biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of VC + GA against COVID-19. Our findings suggested that combinatorial VC and GA treatment for COVID-19 was associated with elevation of immunity and suppression of inflammatory stress, including activation of the T cell receptor signaling pathway, regulation of Fc gamma R-mediated phagocytosis, ErbB signaling pathway and vascular endothelial growth factor signaling pathway. We also identified 17 core targets of VC + GA, which suggest as antimicrobial function. CONCLUSIONS: For the first time, our study uncovered the pharmacological mechanism underlying combined VC and GA treatment for COVID-19. These results should benefit efforts to address the most pressing problem currently facing the world.

Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first reported from Wuhan, Hubei Province, China [1] . The virus spread across China before it could be restrained effectively, then subsequently infected populations worldwide, resulting in a pandemic with increasing death tolls [2] . Clinical manifestations of COVID-19 include acute pneumonia detected via computed tomography imaging or radiological examination. Systemic fever is another visible symptom [3] . SARS-CoV-2 has greater infectivity than severe acute respiratory syndrome-related coronavirus (SARS-CoV), because the former's binding capacity to angiotensin-converting enzyme II is approximately 10-100fold higher than the latter's [4] . Patients infected with SARS-CoV-2 exhibit high mortality rate, especially if they are over 60 years of age [5] . Although the medical diagnosis of COVID-19 is rapid and efficient, effective treatments do not yet exist [6] . Thus, potential agents for treatment should be screened rapidly.

Vitamin C (VC) possesses antiaging, antiviral and antiimmunocompromise properties, making the compound useful for preventing various health conditions [7] . Some evidence suggests that VC supplements may enhance cellular immunological capacity for phagocyte induction, T lymphocyte activation and interferon release [8] . Moreover, clinical studies suggest that the antiviral effects of VC can eliminate virus-caused respiratory complications [9] . In addition, VC appears to be beneficial against the avian coronavirus, altering host susceptibility to viral infection [10] . Notably, VC supplements can reduce viral respiratory infections during influenza, suggesting anti-pneumonia potential [11] . Controlled clinical trials demonstrated that VCsupplemented patients have reduced pneumonia incidence, implying potential effectiveness against lower respiratory tract viral infections [12] . During the SARS epidemic, VC was recommended as preventive medication and for adjuvant therapy that significantly lowered the incidence of pneumonia [13, 14] . In China, clinical trials are being conducted with patients at Wuhan hospitals to determine whether high doses of VC can manage COVID-19 [ClinicalTrials.gov Identifier: NCT04264533]. However, VC overdose has unwanted side effects, including kidney stones and diarrhea [15] . Thus, combining VC with existing medicines or bioactive compounds may enhance the former's therapeutic effectiveness against COVID-19 while minimizing side effects. Rhizoma Glycyrrhizae (Gancao) is common, multifunctional ingredient of traditional Chinese medicine, such as viral infection [16] . Glycyrrhizic acid (GA) is a major bioactive ingredient extracted from Rhizoma Glycyrrhizae. It has evident pharmacological properties, including detoxifying, cough-relieving, anti-inflammatory, antitumor and antibacterial capacity [17] . Furthermore, GA may inhibit propagation of the pseudorabies virus and porcine epidemic diarrhea virus, indicating potential antiviral action [18] . GA has been used in clinical treatment of inflammation-induced diseases [19] . Based on the potent pharmacological properties of both VC and GA, their combined use may effectively manage COVID-19. At this time, no empirical data supports the clinical efficacy of VC + GA treatment against COVID-19 has not been investigated.

However, we can perform bioinformatics analysis as a theoretical evaluation of potential anti-COVID-19 molecular mechanisms of VC + GA to support future clinical trials. Bioinformatics-based network pharmacology has emerged as a powerful tool to reveal active ingredients, biological targets and signaling pathways linked to certain diseases [20] . Our previous studies used network pharmacology to identify anti-disease targets and pathways of certain bioactive components [21, 22] . In this study, we aimed to establish a component-target-pathway network of VC + GA treatment against the novel coronavirus, thereby uncovering anti-COVID-19 processes and mechanisms in detail ( Figure 1 ).

Potential targets were acquired after a thorough analysis of the Traditional Chinese Medicine Systems Pharmacology (TCMSP) [23] , Drugbank [24] , SuperPred, Swiss Target Prediction [25] , ChemMapper [26] , Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN TCM) [27] and SuperPred webserver [28] datasets. Functional targets of VC and GA in humans were selected from the Swiss-Prot and Uniprot databases [29] . Genecard [30] and Online Mendelian Inheritance in Man (OMIM) [31] databases were used to screen SARS-CoV-2 pathogenic targets. All shortlisted targets of VC, GA and SARS-CoV-2 were then subjected to intersection analysis via an online toolkit. Custom Venn diagrams (http://bioinformatics. psb.ugent.be/webtools/Venn/) were created to show correlative targets of VC and GA against COVID-19.

R-language packages 'ClusterProfiler,' 'ReactomePA,' 'org.Hs.e g.Db,' and 'GOplot' were used for analysis and visualization of correlative targets. GO data were analyzed using 'org.Hs.eg.Db,' with cutoffs for enrichment being P < 0.05 and q < 0.05; outputs were bubble charts and Circos-circle charts. The 'pathview' package was used to create pathway diagrams for correlative targets of enriched KEGG pathways; this step allowed for further analysis of the results [32, 33] .

Cytoscape version 3.7.1 was used to construct visualizations of the component-target-pathway network, GO biological processes and KEGG pathways of VC and GA's individual and combined effects against COVID-19 [34] .

We performed pairwise comparisons on bioinformational data of the top 20 biological processes and KEGG-enriched pathways involved in the separate therapeutic effects of VC and GA against COVID-19. We used -log10 (P.adjust) as the heatmap parameter and drew heatmaps in HemI 1.0 [35] .

We used common targets of VC and GA against SARS-CoV-19 as inputs to a STRING database (version 11.0) [36] , creating target-to-target network interactions and a target interaction PPI network diagram. We then analyzed network topology parameters (e.g. median and maximum degrees of freedom) in the Tab Separated Values (TSV) data format using Network Analyzer in Cytoscape version 3.7.1; optimal targets were collected based on degree values. For filtering, the upper limit was maximum degree value in the topology data, and the lower limit was twice the median degree of freedom [37] . The degree of nodes (i.e. quantity of linking edges) indicates the probability distribution of degrees across the entire network [38, 39] .

We screened Genecard and OMIM datasets to identify 426 COVID-19-associated genes. After data correction with Uniprot, we identified 338 VC-and 223 GA-pharmacological action genes. Venn diagrams revealed 34 VC-intersection ( Figure 2A ) and 28 GA-intersection ( Figure 2B ) targets against COVID-19.

The results of GO analysis suggested that the biological processes of core VC targets against COVID-19 were mainly involved in peptidyl-serine phosphorylation, peptidyl-serine modification, regulation of cell-cell adhesion, cellular response to biotic stimulus, positive regulation of nucleocytoplasmic transport, regulation of leukocyte cell-cell adhesion, regulation of T cell activation, response to lipopolysaccharide, T cell activation, blood coagulation, leukocyte cell-cell adhesion, cellular response to external stimulus, hemostasis, coagulation, response to molecule of bacterial origin, platelet activation, fatty acid metabolic process, positive regulation of cell adhesion, regulation of nucleocytoplasmic transport and positive regulation of protein transport ( Figure 3A The GO data indicated that functional processes of core GA targets against COVID-19 were associated with response to lipopolysaccharide, cellular response to abiotic stimulus, cellular response to environmental stimulus, response to molecule of bacterial origin, placenta development, peptidylserine phosphorylation, reproductive structure development, reproductive system development, peptidyl-serine modifica- tion, lipopolysaccharide-mediated signaling pathway, cellular response to external stimulus, platelet activation, regulation of cell-cell adhesion, cellular response to mechanical stimulus, positive regulation of establishment of protein localization, peptidyl-tyrosine autophosphorylation, T cell activation, cellular response to lipopolysaccharide, interaction with host and response to mechanical stimulus ( Figure 4A and B and Supplementary (0030168), regulation of cell-cell adhesion (0022407), response to lipopolysaccharide (0032496), response to molecule of bacterial origin (0002237), T cell activation (0042110), blood coagulation (0007596) and leukocyte cell-cell adhesion (0007159) ( Table 1 ). The top 15 KEGG signaling pathways of VC + GA against COVID-19 were AGE-RAGE signaling pathway in diabetic complications (hsa04933), Aldosterone-regulated sodium reabsorption (hsa04960), EGFR tyrosine kinase inhibitor resistance (hsa04960), ErbB signaling pathway (hsa04012), Fc gamma Rmediated phagocytosis (hsa04666), Glioma (hsa05214), GnRH signaling pathway (hsa04912), Human cytomegalovirus infection (hsa04912), Kaposi sarcoma-associated herpesvirus infection (hsa04912), MicroRNAs in cancer (hsa05206), Non-small cell lung cancer (hsa05206), Proteoglycans in cancer (hsa05205), Serotonergic synapse (hsa04726), TCR signaling pathway (hsa04660) and VEGF signaling pathway (hsa04370) ( Table 2 ). 

Respectively, Figure 6A and B shows the heatmaps depicting GO biological processes and KEGG signaling pathways of VC + GA against COVID-19, respectively. Detailed information regarding the raw data is listed in Supplementary Tables 5 and 6 , see Supplementary Data available online at https://academic.oup.co m/bib.

We created a network visualization of VC + GA-target-GO-KEGG-COVID-19 using the top 20 enriched GO terms and KEGG pathways (Figure 7) . Our result showed that VC and GA shared 10 biological processes and 15 KEGG pathways, representing their combined anti-COVID-19 targets.

As the COVID-19 pandemic has spread worldwide, effective management and treatment strategies targeting SARS-CoV-2 are in urgent demand [40] . Although VC and GA individually have potent pharmacological efficacy against viral pneumonia [41, 42] , no study has investigated their combined effects or potential mechanisms against COVID-19. Here, we used a potent strategy of network pharmacology and bioinformatics (including GO and KEGG) to uncover the integrative pharmacological mechanism of VC + GA against COVID-19. Our findings suggest that VC + GA may be able to suppress COVID-19 through their combined antioxidative, antiviral and anti-inflammatory effects, along with immune system activation. Specifically, notably enriched GO biological processes included T cell activation and leukocyte adhesion. Moreover, according to our KEGG pathway analysis, the pharmacological mechanisms of VC + GA against COVID-19 involved specific modulations of immune responses, such as Fc gamma R-mediated phagocytosis, TCR signaling pathway, VEGF signaling pathway and human cytomegalovirus infection. Fc gamma R-mediated phagocytosis is an essential part of the innate immune response, when neutrophils and macrophages engulf IgG-coated particles [43] . TCR signaling has a key role in determining T cell fate [44] . Also, TCR is important to the differentiation, maintenance and function of regulatory T cells [45] . When VC + GA activates Fc gamma R-mediated phagocytosis and TCR, these processes may facilitate the host to initiate an immune response against COVID-19. VEGF signaling pathway is a major pathway that stimulates blood vessel formation [46] . Although most VEGF studies focused on cancer development, a mouse study demonstrated that exposure to recombinant VEGF dramatically reduced CD4+/CD8+ thymocytes [47] . Additionally, a glioblastoma rodent model showed that VEGF modulates the innate immune response through suppressing immunologic and pro-angiogenic functions of macrophages, suggesting VEGF is also essential for the adaptive immune system [48] .

Our molecular functional analysis revealed that key effectors regulate the anti-COVID-19 properties just described. Effectors include protein kinase C (PKC) family (PRKCA, PRKCB and PRKCE), mitogen-activated protein kinase family (MAPK1, MAPK3 and MAPK14) and lymphocyte-specific protein tyrosine kinase (LCK). PKC alpha, PRKCB and PRKCE are central to immune biology [49, 50] . The first has an important function in different immune cell types. For instance, a PKCα-deficient mouse study showed that pkrc−/− cells were defective in IL-2 suppression because l17a promoter activity was reduced; this finding suggests that PRKCA participates in Th17 cell immune responses [51] . In addition, PRKCA is required for Fc receptors, which acts during IgA (FcalphaR) trafficking to major histocompatibility complex (MHC) class II compartments and FcalphaR-mediated antigen presentation [52] . Moreover, PRKCA promotes M1 macrophage polarization in colon cancer cells through the Mitogen-Activated Protein Kinase (MAPK) pathway [53] . Next, PRKCB is associated with phagocytosis function [54] . A mouse study demonstrated that PRKCB enhancement improves macrophage function in lupus patients with lipopolysaccharide (LPS) tolerance from chronic infection [55] . Also, PRKCB is a negative regulator of retinoic acid-inducible gene I antiviral signal transduction. This process is a key sensor of viral RNA in the cytosol and is therefore critical to establishing an interferonmediated antiviral state [56] . Furthermore, PRKCB is integral to B cell survival and antigenic response, following B cell antigen receptor engagement of naïve B cells [57] . Finally, PRKCE is also necessary for innate immune responses [58] . A PKCε-knockout mouse study showed that prkce−/− macrophages produced fewer inflammatory cytokines, suggesting that the protein kinase is important for macrophage activation and defense against bacterial infection [59] .

Our data implicated MAPK signaling as part of the mechanisms underlying VC + GA antiviral function. MAPK cascades are crucial signaling pathways in the regulation of host immune response to infection [60] . Specifically, MAPK signaling induces pro-inflammatory mediators and activation of antiinflammatory pathways through controlling many downstream effectors [61] . For example, activator protein-1 is a downstream target of the MAPK signaling cascade and a critical regulator of nuclear gene expression during T cell activation [62] . In addition, MAPK pathway inhibition negatively affects T cell activity in breast cancer, suggesting that MAPK activity is required for T cell function [63] .

The final protein kinase that appears to explain the action of VC + GA treatment against COVID-19 is LCK, a tyrosine kinase that contributes to intracellular signaling pathways of lymphocytes. These include transduction of TCR-mediated activation and cytokine production in T cells [64, 65] . Decreases in LCK activity facilitate viral infections such as HIV-1 in T cells [66] .

It has been reported that COVID-19 patients with severe and fatal disease had significantly increase in white blood cell number and decreased lymphocyte and platelet counts [67, 68] . Our findings showed that the VC + GA treatment should exert potent antiviral and anti-inflammatory effects through the activation of immune system, suggesting the possible use of VC + GA as optional treatment of COVID-19. These attributes are consistent with other forms of combined modality therapy against clinical disease, which acts via regulating multiple targets and pathways. In upcoming clinical treatments for COVID-19, VC + GA supplementation may potentiate the therapeutic effectiveness of existing medicines such as Remdesivir. However, more studies are needed to confirm the action of VC + GA on COVID-19, as we currently do not know how the supplements target and influence the virus. Previous reports suggest that VC affects many cellular receptors, such as peroxisome proliferatoractivated receptor α, fibroblast growth factor receptor 2 and angiotensin receptors [69] [70] [71] . Furthermore, considerable evidence exists to show that VC and GA can separately control some signaling pathways, including the three (MAPK, VEGF and PKC signaling), which we identified here using bioinformatics [72] [73] [74] [75] [76] . We thus find VC + GA, a promising supplementary treatment against COVID-19, which is worth further investigation.

In conclusion, network pharmacology revealed that antiinflammation and immunity activation were primary target pathways of the VC + GA treatment against COVID-19. Hopefully, this combination can be applied to the development of effective SARS-CoV-2 treatments, based on the identified functional processes and pharmacological mechanisms.

• Bioinformatics analysis using network pharmacology is a valuable strategy for revealing candidate genes and molecular pathways of bioactive compounds effective against complex diseases.

• Candidate targets and underlying mechanisms of the combined vitamin C (VC) and glycyrrhizic acid (GA) treatment against coronavirus disease 2019 (COVID-19) were identified and visualized.

• Bioinformatics findings indicate that combined VC and GA can act as a potential therapeutic option for COVID-19 treatment.

The data underlying this article are available in the article and in its online supplementary material.

Supplementary data are available online at https://academi c.oup.com/bib.

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health?

Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Coronavirus disease 2019 (COVID-19) in Italy

The challenge of emergency medicine facing the COVID-19 outbreak

Effects of vitamin C on oxidative stress, inflammation, muscle soreness, and strength following acute exercise: meta-analyses of randomized clinical trials

Vitamin C and immune function

Efficacy of vitamin C for the prevention and treatment of upper respiratory tract infection. A meta-analysis in children

Performance traits and immune response of broiler chicks treated with zinc and ascorbic acid supplementation during cyclic heat stress

Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-α/β at the initial stage of influenza a virus (H3N2) infection

Vitamin C for preventing and treating pneumonia

Vitamin C intake and susceptibility to pneumonia

The risk of abuse of vitamin supplements

Pharmacokinetic mechanisms underlying the detoxification effect of Glycyrrhizae Radix et Rhizoma (Gancao): drug metabolizing enzymes, transporters, and beyond

Advances in pharmacological activities and mechanisms of glycyrrhizic acid

Research progress of glycyrrhizic acid on antiviral activity

Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: a randomized placebo-controlled clinical trial

Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology

Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma

To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

DrugBank 5.0: a major update to the DrugBank database for 2018

SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules

ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method

BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of

SuperPred: update on drug classification and target prediction

UniProt: the universal protein knowledgebase

GeneHancer: genome-wide integration of enhancers and target genes in GeneCards

Online Mendelian Inheritance in Man (OMIM), an online catalog of human genes and genetic disorders

Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data

Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma

To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis

Pharmacological biotargets and the molecular mechanisms of oxyresveratrol treating colorectalcancer: network and experimental analyses

HemI: a toolkit for illustrating heatmaps

STRING v11: proteinprotein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Network analysis, and human and animal studies disclose the anticystitis glandularis effects of vitamin C

Anti-colorectal cancer biotargets and biological mechanisms of puerarin: study of molecular networks

Preventing a covid-19 pandemic

Antiviral activity of a complex of the glycyrrhizic acidalpha-glutamyltryptophan against the experimental lethal influenza infection in white mice caused by the oseltamivir-resistant strain of the virus

Fc gamma R-mediated phagocytosis stimulates localized pinocytosis in human neutrophils

A mechanism for expansion of regulatory T-cell repertoire and its role in selftolerance

T cell receptor signalling in the control of regulatory T cell differentiation and function

VEGF in signaling and disease: beyond discovery and development

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression

VEGF as a modulator of the innate immune response in glioblastoma

Regulation of immune system cell functions by protein kinase

Protein kinase C inhibitors for immune disorders

The kinase PKCα selectively upregulates interleukin-17A during Th17 cell immune responses

Protein kinase C-alpha and -delta are required for FcalphaR (CD89) trafficking to MHC class II compartments and FcalphaR-mediated antigen presentation

PKCα in colon cancer cells promotes M1 macrophage polarization via MKK3/6-P38 MAPK pathway

Decreased protein kinase C-β type II associated with the prominent endotoxin exhaustion in the macrophage of FcGRIIb−/− lupus prone mice is revealed by phosphoproteomic analysis

Decreased protein kinase C-β type II associated with the prominent endotoxin exhaustion in the macrophage of FcGRIIb−/− lupus prone mice is revealed by phosphoproteomic analysis

Conventional protein kinase C-α (PKC-α) and PKC-β negatively regulate RIG-I antiviral signal transduction

Conventional protein kinase C-α (PKC-α) and PKC-β negatively regulate RIG-I antiviral signal transduction

Protein kinase Cβ is critical for the metabolic switch to glycolysis following Bcell antigen receptor engagement

Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection

MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response

Mitogen-activated protein kinases in innate immunity

AP-1 transcription factors as regulators of immune responses in cancer

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

The exon 7-spliced Lck isoform in T lymphocytes: a potential regulator of p56lck signaling pathways

Lymphocyte-specific protein tyrosine kinase (LCK) is involved in the aryl hydrocarbon receptor-mediated impairment of immunoglobulin secretion in human primary B cells

HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity

Clinical and imaging features of COVID-19, Radiol Infect Dis 2020

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice

Ascorbic acid attenuates cell stress by activating the fibroblast growth factor 21/fibroblast growth factor receptor 2/adiponectin pathway in HepG2 cells

Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II

Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta

Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice

Ascorbic acid induces necrosis in human laryngeal squamous cell carcinoma via ROS, PKC, and calcium signaling

Compound ammonium glycyrrhizin protects hepatocytes from injury induced by lipopolysaccharide/florfenicol through oxidative stress and a MAPK pathway

Glycyrrhizic acid suppresses 1,2-dimethylhydrazine-induced colon tumorigenesis in Wistar rats: alleviation of inflammatory, proliferation, angiogenic, and apoptotic markers